Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which sedative gets you off the breathing tube faster after liver surgery?

NCT ID NCT07611344

Symptom relief Sponsor: Xuyu Zhang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 4 times

Summary

This study compares two sedative drugs, remimazolam and propofol, to see which one helps patients wake up faster after laparoscopic liver surgery. About 82 adults aged 18-80 having this surgery will be randomly assigned to receive one of the two drugs. The main goal is to measure how quickly the breathing tube can be removed after surgery, and researchers will also track side effects like nausea, low blood pressure, and sore throat.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

82 people

The number who actually took part.

Started

May 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1): Planned to undergo laparoscopic hepatectomy. 2): Has signed the informed consent form. 3): Aged 18 to 80 years. 4): Body Mass Index (BMI) ranging from 18 to 28 kg/m². 5): American Society of Anesthesiologists (ASA) physical status classification I to III. Exclusion Criteria: * 1）: Severe cardiopulmonary dysfunction, or hepatic/renal dysfunction. 2）: Diagnosis of neuropsychiatric disorders. 3）: Pregnant or lactating women. 4）: A history of allergy or contraindication to benzodiazepines, propofol, or any of their components.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Laparoscopic hepatectomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Laparoscopic hepatectomy

Contacts and locations

Locations

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.